Metastatic Urothelial Carcinoma research hub
5 indexed studies · 1 currently recruiting
- active not recruitingPHASE1, PHASE2
A Study of Efficacy and Safety of Sacituzumab Tirumotecan (MK-2870) Plus Enfortumab Vedotin (EV) With and Without Pembrolizumab in Advanced Urothelial Carcinoma (MK-3475-04C/KEYMAKER-U04)
This study is looking at a new combination of treatments for advanced bladder cancer. Doctors want to see how safe and effective a new drug, sacituzumab tirumotecan, is when given with enfortumab vedotin. It's a key step in finding better ways to treat this type of cancer.
United States · Canada · France - active not recruitingPHASE1, PHASE2
A Study of Efficacy and Safety of Pembrolizumab Plus Enfortumab Vedotin (EV) +/- Investigational Agents in First-Line Metastatic Urothelial Carcinoma (mUC) (MK-3475-04B/KEYMAKER-U04)
This study looks at new drug combinations for advanced bladder cancer. Doctors want to see if adding different medicines to pembrolizumab and enfortumab vedotin (EV) works better and is safe. The goal is to find new, effective treatments for patients.
United States · Australia · Canada - recruitingPHASE1
A Study of NX-1607 in Adults With Advanced Malignancies
This study is looking into a new treatment called NX-1607 for various advanced cancers, including ovarian, stomach, and lung cancer. It aims to see how safe the treatment is and if it can help fight the cancer, sometimes combined with another drug called Paclitaxel.
United States · United Kingdom - authorisedTherapeutic exploratory (Phase II)
Maintenance AVElumab after SECond line platinum-based chemotherapy for metastatic urothelial carcinoma: AVESEC trial - GOIRC-02-2025
This study is looking at a new treatment called avelumab for people with a type of cancer that has spread. It compares avelumab to other common care after initial chemotherapy to see how well it works and if it helps people live longer and feel better.
Italy - active not recruitingPHASE1, PHASE2
Testing the Addition of Tazemetostat to the Immunotherapy Drug, Pembrolizumab (MK-3475), in Advanced Urothelial Carcinoma
This study is looking into a new treatment for advanced bladder cancer. It combines two drugs, tazemetostat and pembrolizumab, to see if they work better together. Doctors want to find the safest dose and understand how well this combination fights the cancer.
United States · Canada